Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Standard Lithium Ltd — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $300.64 (market cap $8.04B), while Standard Lithium Ltd trades at $2.33 (market cap $577.14M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 13.9× Standard Lithium Ltd's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| BIO | SLI | |
|---|---|---|
Market Cap | $8.04B | $577.14M |
Sector | Health | Basic Materials |
52-Week High | $339.75 | $5.65 |
52-Week Low | $241.71 | $2.29 |
Enterprise Value | $7.85B | $436.34M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
SLI trades at $2.29, down 6.91% today, with a bearish technical trend but oversold RSI readings. The company reported a net loss of $48.40 million in 2025, though it secured a $225 million DOE grant and key construction contracts for its Arkansas lithium project. Analyst consensus is unanimously bullish with 3 buy ratings.
The investment case hinges on successful project execution and lithium market dynamics. Near-term risks include cash burn and execution delays, but long-term upside exists if production targets are met. Investors should weigh high operational losses against strong institutional backing and strategic partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
